Vimarsana
Biggest News Aggregation in the World

Page 41 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Export Today - Breaking & Trending Today

Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors - Vimarsana News

Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors

Published: December 6, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

Source: prnewswire.com
Related Topics:
United StatesMikael DolstenPeterk HonigBarrye GreeneOffice Of Drug SafetyAlopexx EnterprisesDrug Information AssociationAmerican Society For Clinical PharmacologyMedicine ConsortiumHead Of Global Regulatory AffairsKaryopharm Selective Inhibitor Of Nuclear ExportEuropean UnionKaryopharm Therapeutics IncMerck Research LaboratoriesInternational Conference On HarmonisationSteering CommitteeDrug AdministrationEuropean CommissionColumbia UniversityPrnewswire Karyopharm Therapeutics IncExchange CommissionGroup Head Of DevelopmentCentre Of Regulatory ExcellenceLead DirectorSenior Vice President
Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer - Vimarsana News

Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer

Published: December 2, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

Source: prnewswire.com
Related Topics:
United StatesSharon ShachamSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncEuropean CommissionDrug AdministrationPrnewswire Karyopharm Therapeutics IncExchange CommissionEuropean UnionKaryopharm Selective Inhibitor Of Nuclear ExportInformation DepartmentAmerican Cancer SocietyChief Scientific OfficerSelective InhibitorNuclear ExportNew Drug ApplicationMedical InformationFetal ToxicityKaryopharm TherapeuticsPrivate Securities Litigation Reform ActQuarterly ReportShow CommonAccessed NovemberEpidemiology DatabaseKaryopharm Therapeutics Inc
Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer - Vimarsana News

Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer

Published: December 2, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

Source: prnewswire.com
Related Topics:
United StatesSharon ShachamSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncEuropean CommissionDrug AdministrationPrnewswire Karyopharm Therapeutics IncExchange CommissionEuropean UnionKaryopharm Selective Inhibitor Of Nuclear ExportInformation DepartmentAmerican Cancer SocietyChief Scientific OfficerSelective InhibitorNuclear ExportNew Drug ApplicationMedical InformationFetal ToxicityKaryopharm TherapeuticsPrivate Securities Litigation Reform ActQuarterly ReportShow CommonAccessed NovemberEpidemiology DatabaseKaryopharm Therapeutics Inc
Karyopharm to Host Virtual Investor Day on December 8, 2021 - Vimarsana News

Karyopharm to Host Virtual Investor Day on December 8, 2021

Published: December 1, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...

Source: prnewswire.com
Related Topics:
Srinivas TantravahiRafael FonsecaRobert ColemanCristina GasparettoGuillermo Garcia ManeroVicky MakkerKaryopharm Therapeutics IncUniversity Of UtahEuropean CommissionMd Anderson Cancer CenterPrnewswire Karyopharm Therapeutics IncDuke University Medical CenterKaryopharm Selective Inhibitor Of Nuclear ExportUs Oncology ResearchMemorial Sloan Kettering Cancer CenterInvestor DayDuke University MedicalMemorial Sloan Kettering CancerKaryopharm TherapeuticsSelective InhibitorNuclear ExportKaryopharm Therapeutics Inc
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published: December 1, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
Karyopharm Therapeutics IncKaryopharm Selective Inhibitor Of Nuclear ExportCompensation Committee Of Karyopharm Board DirectorsEuropean CommissionKaryopharm TherapeuticsCompensation CommitteeNasdaq Listing RuleSelective InhibitorNuclear ExportKaryopharm Therapeutics Inc